CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acrivon Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acrivon Therapeutics Inc
480 Arsenal Way, Suite 100
Phone: (617) 207-8979p:617 207-8979 WATERTOWN, MA  02472  United States Ticker: ACRVACRV
Business Summary
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing precision medicines for oncology and inflammatory diseases utilizing its proprietary Generative artificial intelligence (AI)-driven, Phosphoproteomics Acrivon Predictive Precision Proteomics (AP3) platform. Its lead program, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase II trial for endometrial cancer (EC). It is advancing ACR-7280, its next AP3-enabled innovation program, a first-in-class, oral, highly selective CDK11 inhibitor development candidate, in IND-enabling studies. Its immunology and inflammation pipeline, ACR-525, a Phase II-ready, oral, highly selective JAK1 inhibitor. Additionally, the Company has a preclinical PKC? inhibitor preclinical program, an attractive target for T-cell-driven autoimmune and inflammatory diseases, with the potential to be developed in combination with ACR-525 and other I&I therapies.
(Source: 6-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, President, Chief Executive Officer PeterBlume-Jensen 64 10/1/2020 3/1/2018
Chief Financial Officer AdamLevy 61 4/1/2025 4/1/2025
Chief Operating Officer EricDevroe 48 8/1/2022 10/1/2020
9 additional Officers and Directors records available in full report.

Business Names
Business Name
Acrivon AB
Acrivon Securities Corporation
Acrivon Therapeutics Inc
ACRV

General Information
Number of Employees: 74 (As of 12/31/2025)
Outstanding Shares: 42,853,362 (As of 8/7/2026)
Shareholders: 6
Stock Exchange: NASD
Federal Tax Id: 825125532
Fax Number: (302) 636-5454


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 14, 2026